

Supplementary Table S1. ALBI Score Grading for various BCLC Stages

		ALBI-Score			P value
		Grade 1	Grade 2	Grade 3	
		N (%)	N (%)	N (%)	
BCLC	1	46 (41.8)	59 (53.6)	5 (4.5)	<0.001
	2	18 (30.5)	34 (57.6)	7 (11.9)	
	3	19 (27.5)	45 (65.2)	5 (7.2)	
	4	0 (0)	10 (30.3)	23 (69.7)	

Abbreviations: ALBI Albumin-Bilirubin-Score; BCLC Barcelona Clinic Liver Cancer

Supplementary Table S2. Survival time of patients in time-period 1 vs. time-period 2 including OLT

		Overall survival TP 1 (months)			Overall survival TP 2 (months)			P value (log rank)
Variable		N=128	Median	95% CI	N=148	Median	95% CI	
Age	<70	42	14.3	8.6–20.0	62	20.7	10.8–30.7	0.176
	≥70	86	24.2	19.5–28.8	86	19.8	15.0–24.6	
Sex	male	109	22.4	17.0–27.7	127	20.1	15.6–24.7	0.841
	female	19	12.4	4.3–20.4	21	18.1	11.4–24.7	
Liver cirrhosis	Present	106	21.6	15.5–27.7	101	20.2	7.5–65.9	0.279
	Absent	22	22.0	8.7–35.4	47	36.7	16.0–24.3	
Etiology	Alcohol	69	18.9	11.5–26.3	70	18.0	13.8–22.3	0.004
	Viral	28	27.0	9.2–44.8	27	53.3	19.4–87.2	
	NASH	15	26.2	4.8–47.7	28			
	Other	6	21.9	16.8–27.0	7	14.1	0.0–39.5	
Ascites	Present	28	5.4	0.0–11.7	41	11.8	1.5–22.1	<0.001
	Absent	98	24.2	19.7–28.7	106	27.8	11.5–44.1	
Child-Pugh	No cirrhosis	22	22.0	8.7–35.4	47	36.7	7.5–65.9	<0.001
	A	55	28.7	19.8–37.6	61	27.0	12.8–41.3	
	B	38	15.2	9.3–21.0	27	11.8	0.9–22.7	
	C	13	1.8	0.0–3.6	13	5.6	0.0–13.7	
BCLC	A	53	33.1	11.2–55.1	59	52.8	20.1–85.5	<0.001
	B	32	24.2	12.1–36.2	29	27.0	6.5–47.6	
	C	23	10.4	5.9–15.0	46	10.0	6.1–13.9	
	D	20	1.8	0.9–2.6	14	1.9	0.0–6.1	
Focality	Unifocal	55	22.0	15.4–28.6	72	52.8	20.6–85.0	0.002
	Multifocal	73	21.9	16.0–27.8	76	12.8	8.9–16.6	
Up-to-seven	≤7	65	28.5	14.9–42.1	76	34.6	7.7–61.4	<0.001
	>7	62	12.9	8.5–17.2	72	11.0	8.3–13.8	
SBL	Present	120	22.2	18.0–26.4	16	10.5	5.7–15.2	<0.001
	Absent	7	2.2	1.7–2.7	132	21.2	12.5–29.9	
MVI	Present	105	24.2	19.6–28.7	36	4.8	3.2–6.4	<0.001
	Absent	22	7.4	2.1–12.7	112	30.6	16.5–44.6	

Ln. >2cm	Present	23	12.6	8.6–29.3	18	4.8	2.2–7.4	<0.001
	Absent	103	22.7	16.5–29.0	127	27.0	16.5–37.6	
CRP	Raised	58	12.1	7.2–16.9	62	11.2	7.7–65.7	<0.001
	Normal	67	33.1	20.1–46.2	85	36.7	7.0–15.3	
CAD	Present	13	19.4	4.1–34.6	21	16.0	15.9–24.4	0.454
	Absent	112	21.9	16.6–27.1	127	20.1		
CKD	Present	10	14.3	12.2–16.4	19	42.8	0.0–86.0	0.299
	Absent	115	22.0	17.6–26.5	128	20.2	16.0–24.3	
Hypertension	Present	80	24.0	17.5–30.5	87	18.1	12.9–23.3	0.866
	Absent	45	18.2	9.6–26.9	61	21.2	8.9–33.4	
DM	Present	38	18.9	8.7–29.1	50	20.5	9.0–31.9	0.610
	Absent	90	22.2	15.4–29.0	98	18.7	13.3–24.1	
BMI	<25	28	18.9	3.4–34.4	47	19.8	9.3–30.3	0.674
	≥25	77	25.4	18.2–32.6	91	20.5	9.1–31.8	
AFP	Raised (>7)	76	15.2	9.6–20.7	80	14.1	9.8–18.3	<0.001
	Normal	49	33.2	21.3–45.1	67	34.6	5.3–63.8	
ALBI score	Grade 1	18	33.2	9.8–56.6	65	34.6	26.4–42.7	<0.001
	Grade 2	81	22.0	15.7–28.4	67	15.8	11.5–20.1	
	Grade 3	24	7.6	0.0–19.0	16	3.9	0.8–6.9	
First-line therapy	Surgical/ OLT	21	63.2	36.0–90.4	21			<0.001
	RFA/ MWA	13	48.7	13.9–83.5	32	52.8	0.0–109.7	
	TACE	55	24.0	20.1–27.8	21	27.0	15.9–38.1	
	Systemic	16	12.6	8.7–16.4	59	11.8	8.8–14.8	
	None	23	2.1	1.3–2.8	15	1.9	0.4–3.4	
ASA	Present	24	24.2	9.0–39.4	35	53.3	0.0–110.2	0.248
	Absent	104	21.6	17.2–26.0	113	18.1	14.2–21.9	

Abbreviations: BCLC, Barcelona-Clinic Liver-Cancer Staging, CRP, C-reactive protein, BMI, body mass index, AFP, alpha-fetoprotein, ALBI, albumin-bilirubin score, SBL, sclerotic bone lesions, ASA, acetylsalicylic acid, NASH, non-alcoholic steatosis hepatitis, MVI, microvascular invasion, Ln., lymphnode, CAD, coronary artery disease, CKD, chronic kidney disease, DM, diabetes mellitus